What BMI do you need for Zepbound under Kaiser Permanente Mid-Atlantic?

For weight loss on Employer / Commercial Insurance plans, Kaiser Permanente Mid-Atlantic requires a BMI of 27 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.

How long does a Zepbound approval last with Kaiser Permanente Mid-Atlantic?

Initial approvals last 6 months, and renewals are granted in 6-month periods.

What does Kaiser Permanente Mid-Atlantic require to renew Zepbound?

At least 5% weight loss from the starting weight and Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to =27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members.

How current is this information?

This page reflects Kaiser Permanente Mid-Atlantic's written policy as of June 2, 2026, last verified against the source document on June 5, 2026.

Does Kaiser Permanente Mid-Atlantic cover Zepbound?

Zepbound for Weight Loss

What Kaiser Permanente Mid-Atlantic requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 27 or higher
BMI of 27 or higher with a weight-related condition (CVD, stroke, HTN, T2DM, CKD, CHD, PCOS, dyslipidemia, MASH, MASLD, idiopathic intracranial hypertension, and osteoarthritis in weight-bearing joints)
3 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (semaglutide (for overweight or obesity)) for at least 90 days
Prior trial of phentermine, diethylpropion, phentermine/topiramate (generic), Qsymia, naltrexone/bupropion (generic), and Contrave for at least 3 months

Qualification pathways

You can qualify through any one of these.

Zepbound for weight loss — BMI 27 to <30 with comorbidity (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 27 to <30 kg/m2
At least ONE qualifying weight-related comorbidity
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 30 to <35 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 30 to <35 kg/m2
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 35 to <40 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 35 to <40 kg/m2
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI >=40 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Currently enrolled in and/or following a lifestyle intervention program (to begin at or before medication initiation) and will continue lifestyle modifications
Baseline BMI >=40 kg/m2
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Documentation to bring

Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is an Endocrinologist, Pediatrician, or Weight Management Specialist
Patient age documentation (>=18 years)
Documented baseline weight within past 30 days
Documented baseline BMI
Documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Detailed diet and exercise log for past 90-180 days (lifestyle interventions with nutrition and physical activity components)
For BMI 27 to <30: documentation of at least one qualifying weight-related comorbidity
For BMI 27 to <35: documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documentation that Zepbound is not being used in combination with another GLP-1 RA or GIP/GLP-1 RA

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for at least 5% weight loss from the starting weight and Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI >=27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Combination use with another GIP/GLP-1 RA or GLP-1 RA not permitted

Policy note: Zepbound for weight loss requires prior documented failure/intolerance/contraindication to semaglutide for overweight or obesity (3-month trial at maximum tolerated dose) — this is a GLP-1 RA step-therapy requirement specific to Zepbound. Lifestyle documentation requirement is more specific than Wegovy: detailed diet and exercise log for past 90-180 days required. Age minimum is 18 (vs 12 for Saxenda/Wegovy). The BMI tier criteria from the general weight management section apply to Zepbound as they do to Wegovy and Saxenda, with the additional semaglutide step-therapy layer. Prior oral weight management drug step therapy applies to BMI 27 to <35 tiers.

Policy effective June 2, 2026 · verified June 5, 2026 · source: hmo-exchange-prior-authorization-criteria-en.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 27 or higher
BMI of 27 or higher with a weight-related condition (CVD, stroke, HTN, T2DM, CKD, CHD, PCOS, dyslipidemia, MASH, MASLD, idiopathic intracranial hypertension, and osteoarthritis in weight-bearing joints)
3 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (semaglutide (for overweight or obesity)) for at least 90 days
Prior trial of phentermine, diethylpropion, phentermine/topiramate (generic), Qsymia, naltrexone/bupropion (generic), and Contrave for at least 3 months

Qualification pathways

You can qualify through any one of these.

Zepbound for weight loss — BMI 27 to <30 with comorbidity (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 27 to <30 kg/m2
At least ONE qualifying weight-related comorbidity
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 30 to <35 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 30 to <35 kg/m2
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 35 to <40 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 35 to <40 kg/m2
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI >=40 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Currently enrolled in and/or following a lifestyle intervention program (to begin at or before medication initiation) and will continue lifestyle modifications
Baseline BMI >=40 kg/m2
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Documentation to bring

Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is an Endocrinologist, Pediatrician, or Weight Management Specialist
Patient age documentation (>=18 years)
Documented baseline weight within past 30 days
Documented baseline BMI
Documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Detailed diet and exercise log for past 90-180 days (lifestyle interventions with nutrition and physical activity components)
For BMI 27 to <30: documentation of at least one qualifying weight-related comorbidity
For BMI 27 to <35: documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documentation that Zepbound is not being used in combination with another GLP-1 RA or GIP/GLP-1 RA

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for at least 5% weight loss from the starting weight and Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI >=27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Combination use with another GIP/GLP-1 RA or GLP-1 RA not permitted

Policy note: Zepbound for weight loss requires prior documented failure/intolerance/contraindication to semaglutide for overweight or obesity (3-month trial at maximum tolerated dose) — this is a GLP-1 RA step-therapy requirement specific to Zepbound. Lifestyle documentation requirement is more specific than Wegovy: detailed diet and exercise log for past 90-180 days required. Age minimum is 18 (vs 12 for Saxenda/Wegovy). The BMI tier criteria from the general weight management section apply to Zepbound as they do to Wegovy and Saxenda, with the additional semaglutide step-therapy layer. Prior oral weight management drug step therapy applies to BMI 27 to <35 tiers.

Policy effective June 2, 2026 · verified June 5, 2026 · source: hmo-exchange-prior-authorization-criteria-en.pdf

Federal Employee Program

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 27 or higher
BMI of 27 or higher with a weight-related condition (CVD, stroke, HTN, T2DM, CKD, CHD, PCOS, dyslipidemia, MASH, MASLD, idiopathic intracranial hypertension, and osteoarthritis in weight-bearing joints)
3 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (semaglutide (for overweight or obesity)) for at least 90 days
Prior trial of phentermine, diethylpropion, phentermine/topiramate (generic), Qsymia, naltrexone/bupropion (generic), and Contrave for at least 3 months

Qualification pathways

You can qualify through any one of these.

Zepbound for weight loss — BMI 27 to <30 with comorbidity (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 27 to <30 kg/m2
At least ONE qualifying weight-related comorbidity
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 30 to <35 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 30 to <35 kg/m2
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI 35 to <40 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Actively adhering to prescriber-documented lifestyle interventions (detailed diet and exercise log for past 90-180 days) and will continue lifestyle modifications
Baseline BMI 35 to <40 kg/m2
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Zepbound for weight loss — BMI >=40 (after semaglutide step therapy)

All of:

Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
Age >= 18 years
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Currently enrolled in and/or following a lifestyle intervention program (to begin at or before medication initiation) and will continue lifestyle modifications
Baseline BMI >=40 kg/m2
Documented baseline weight within past 30 days
Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Documentation to bring

Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is an Endocrinologist, Pediatrician, or Weight Management Specialist
Patient age documentation (>=18 years)
Documented baseline weight within past 30 days
Documented baseline BMI
Documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial at maximum tolerated dose of semaglutide for overweight or obesity
Detailed diet and exercise log for past 90-180 days (lifestyle interventions with nutrition and physical activity components)
For BMI 27 to <30: documentation of at least one qualifying weight-related comorbidity
For BMI 27 to <35: documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial of qualifying oral weight management medication
Documentation that Zepbound is not being used in combination with another GLP-1 RA or GIP/GLP-1 RA

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for at least 5% weight loss from the starting weight and Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI >=27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Combination use with another GIP/GLP-1 RA or GLP-1 RA not permitted

Policy note: Zepbound for weight loss requires prior documented failure/intolerance/contraindication to semaglutide for overweight or obesity (3-month trial at maximum tolerated dose) — this is a GLP-1 RA step-therapy requirement specific to Zepbound. Lifestyle documentation requirement is more specific than Wegovy: detailed diet and exercise log for past 90-180 days required. Age minimum is 18 (vs 12 for Saxenda/Wegovy). The BMI tier criteria from the general weight management section apply to Zepbound as they do to Wegovy and Saxenda, with the additional semaglutide step-therapy layer. Prior oral weight management drug step therapy applies to BMI 27 to <35 tiers.

Policy effective June 2, 2026 · verified June 5, 2026 · source: hmo-exchange-prior-authorization-criteria-en.pdf

Zepbound for Osa

What Kaiser Permanente Mid-Atlantic requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 35 or higher
3 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (Wegovy (semaglutide for overweight or obesity) and liraglutide for overweight or obesity) for at least 90 days
Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

OSA — BMI >=50 (no prior GLP-1 step therapy required at this BMI tier)

All of:

Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI >=30
PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
Age >= 18 years
Documented baseline weight within past 30 days
Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
Baseline BMI >=50 kg/m2
Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

OSA — BMI 35 to <50 (requires prior GLP-1 step therapy)

All of:

Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI >=30
PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
Age >= 18 years
Documented baseline weight within past 30 days
Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
Baseline BMI >=35 to <50 kg/m2
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight or obesity, followed by semaglutide for overweight or obesity)
Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

Documentation to bring

Moderate-to-severe OSA diagnosis confirmed by polysomnography within past year (AHI 15-29 for moderate, AHI >=30 for severe)
Documentation of PAP therapy status: either inability to use PAP (documented anxiety, nasal/oral discomfort) OR documentation of PAP use for at least 3 months with plan to continue
Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is a Pulmonologist or Weight Management Specialist
Patient age documentation (>=18 years)
Documented baseline weight within past 30 days
Documented baseline BMI
Prescriber-documented lifestyle interventions with nutrition and physical activity components (90 days)
For BMI 35 to <50: documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight/obesity followed by semaglutide for overweight/obesity)
Confirmation patient is not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
Confirmation of absence of all reasons for non-coverage (T1/T2DM, central/mixed sleep apnea, prior/planned surgical treatment for OSA or obesity, significant renal/pulmonary/liver disease, other relevant comorbidities/medications, pancreatitis history, MTC/MEN2 history)

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for 25% improvement in AHI from baseline. Must continue actively adhering to prescriber-documented lifestyle interventions (with nutrition and physical activity components). BMI >=27 kg/m2 required. No reasons for non-coverage. Baseline BMI is explicitly NOT re-evaluated at continuation — policy states 'do not consider baseline BMI over the course of treatment; baseline BMI was considered when this therapy course was initially approved.'.

Not covered when

Type 2 diabetes
Central or mixed sleep apnea
Prior or planned surgical or minimally invasive treatment for OSA or obesity
Significant renal, pulmonary, or liver disease
Other comorbidities or medications that may affect weight or daytime sleepiness
Prior acute or chronic pancreatitis
Personal or family history of MTC or MEN2
Currently prescribed another GLP-1 RA or GIP/GLP-1 RA
Type 1 diabetes

Policy note: OSA indication applies to Zepbound ONLY. Polysomnography must be within the past year. Moderate OSA: AHI 15-29; severe OSA: AHI >=30. PAP therapy requirement: patient must either be unable to use PAP OR have used PAP for at least 3 months (and plan to continue). For BMI >=50: no prior GLP-1 step therapy required. For BMI 35 to <50: requires prior failure of Wegovy (or liraglutide for obesity followed by semaglutide for obesity) — 3-month trial at maximum tolerated dose. Note: policy states that if liraglutide or semaglutide are prescribed for OSA indication, Zepbound's OSA criteria will be applied. Continuation: baseline BMI explicitly not re-evaluated; continuation based on 25% AHI improvement, lifestyle adherence, BMI >=27, and no reasons for non-coverage. Exclusions are based on SURMOUNT-OSA trial exclusion criteria.

Policy effective June 2, 2026 · verified June 5, 2026 · source: hmo-exchange-prior-authorization-criteria-en.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 35 or higher
3 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (Wegovy (semaglutide for overweight or obesity) and liraglutide for overweight or obesity) for at least 90 days
Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

OSA — BMI >=50 (no prior GLP-1 step therapy required at this BMI tier)

All of:

Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI >=30
PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
Age >= 18 years
Documented baseline weight within past 30 days
Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
Baseline BMI >=50 kg/m2
Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

OSA — BMI 35 to <50 (requires prior GLP-1 step therapy)

All of:

Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI >=30
PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
Age >= 18 years
Documented baseline weight within past 30 days
Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
Baseline BMI >=35 to <50 kg/m2
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight or obesity, followed by semaglutide for overweight or obesity)
Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

Documentation to bring

Moderate-to-severe OSA diagnosis confirmed by polysomnography within past year (AHI 15-29 for moderate, AHI >=30 for severe)
Documentation of PAP therapy status: either inability to use PAP (documented anxiety, nasal/oral discomfort) OR documentation of PAP use for at least 3 months with plan to continue
Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is a Pulmonologist or Weight Management Specialist
Patient age documentation (>=18 years)
Documented baseline weight within past 30 days
Documented baseline BMI
Prescriber-documented lifestyle interventions with nutrition and physical activity components (90 days)
For BMI 35 to <50: documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight/obesity followed by semaglutide for overweight/obesity)
Confirmation patient is not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
Confirmation of absence of all reasons for non-coverage (T1/T2DM, central/mixed sleep apnea, prior/planned surgical treatment for OSA or obesity, significant renal/pulmonary/liver disease, other relevant comorbidities/medications, pancreatitis history, MTC/MEN2 history)

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for 25% improvement in AHI from baseline. Must continue actively adhering to prescriber-documented lifestyle interventions (with nutrition and physical activity components). BMI >=27 kg/m2 required. No reasons for non-coverage. Baseline BMI is explicitly NOT re-evaluated at continuation — policy states 'do not consider baseline BMI over the course of treatment; baseline BMI was considered when this therapy course was initially approved.'.

Not covered when

Type 2 diabetes
Central or mixed sleep apnea
Prior or planned surgical or minimally invasive treatment for OSA or obesity
Significant renal, pulmonary, or liver disease
Other comorbidities or medications that may affect weight or daytime sleepiness
Prior acute or chronic pancreatitis
Personal or family history of MTC or MEN2
Currently prescribed another GLP-1 RA or GIP/GLP-1 RA
Type 1 diabetes

Policy note: OSA indication applies to Zepbound ONLY. Polysomnography must be within the past year. Moderate OSA: AHI 15-29; severe OSA: AHI >=30. PAP therapy requirement: patient must either be unable to use PAP OR have used PAP for at least 3 months (and plan to continue). For BMI >=50: no prior GLP-1 step therapy required. For BMI 35 to <50: requires prior failure of Wegovy (or liraglutide for obesity followed by semaglutide for obesity) — 3-month trial at maximum tolerated dose. Note: policy states that if liraglutide or semaglutide are prescribed for OSA indication, Zepbound's OSA criteria will be applied. Continuation: baseline BMI explicitly not re-evaluated; continuation based on 25% AHI improvement, lifestyle adherence, BMI >=27, and no reasons for non-coverage. Exclusions are based on SURMOUNT-OSA trial exclusion criteria.

Policy effective June 2, 2026 · verified June 5, 2026 · source: hmo-exchange-prior-authorization-criteria-en.pdf

Federal Employee Program

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 35 or higher
3 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (Wegovy (semaglutide for overweight or obesity) and liraglutide for overweight or obesity) for at least 90 days
Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

OSA — BMI >=50 (no prior GLP-1 step therapy required at this BMI tier)

All of:

Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI >=30
PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
Age >= 18 years
Documented baseline weight within past 30 days
Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
Baseline BMI >=50 kg/m2
Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

OSA — BMI 35 to <50 (requires prior GLP-1 step therapy)

All of:

Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI >=30
PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
Age >= 18 years
Documented baseline weight within past 30 days
Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
Baseline BMI >=35 to <50 kg/m2
Documented intolerance, contraindication, or failure to lose and maintain >=5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight or obesity, followed by semaglutide for overweight or obesity)
Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

Documentation to bring

Moderate-to-severe OSA diagnosis confirmed by polysomnography within past year (AHI 15-29 for moderate, AHI >=30 for severe)
Documentation of PAP therapy status: either inability to use PAP (documented anxiety, nasal/oral discomfort) OR documentation of PAP use for at least 3 months with plan to continue
Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is a Pulmonologist or Weight Management Specialist
Patient age documentation (>=18 years)
Documented baseline weight within past 30 days
Documented baseline BMI
Prescriber-documented lifestyle interventions with nutrition and physical activity components (90 days)
For BMI 35 to <50: documentation of intolerance, contraindication, or failure to lose/maintain >=5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight/obesity followed by semaglutide for overweight/obesity)
Confirmation patient is not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
Confirmation of absence of all reasons for non-coverage (T1/T2DM, central/mixed sleep apnea, prior/planned surgical treatment for OSA or obesity, significant renal/pulmonary/liver disease, other relevant comorbidities/medications, pancreatitis history, MTC/MEN2 history)

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for 25% improvement in AHI from baseline. Must continue actively adhering to prescriber-documented lifestyle interventions (with nutrition and physical activity components). BMI >=27 kg/m2 required. No reasons for non-coverage. Baseline BMI is explicitly NOT re-evaluated at continuation — policy states 'do not consider baseline BMI over the course of treatment; baseline BMI was considered when this therapy course was initially approved.'.

Not covered when

Type 2 diabetes
Central or mixed sleep apnea
Prior or planned surgical or minimally invasive treatment for OSA or obesity
Significant renal, pulmonary, or liver disease
Other comorbidities or medications that may affect weight or daytime sleepiness
Prior acute or chronic pancreatitis
Personal or family history of MTC or MEN2
Currently prescribed another GLP-1 RA or GIP/GLP-1 RA
Type 1 diabetes

Policy note: OSA indication applies to Zepbound ONLY. Polysomnography must be within the past year. Moderate OSA: AHI 15-29; severe OSA: AHI >=30. PAP therapy requirement: patient must either be unable to use PAP OR have used PAP for at least 3 months (and plan to continue). For BMI >=50: no prior GLP-1 step therapy required. For BMI 35 to <50: requires prior failure of Wegovy (or liraglutide for obesity followed by semaglutide for obesity) — 3-month trial at maximum tolerated dose. Note: policy states that if liraglutide or semaglutide are prescribed for OSA indication, Zepbound's OSA criteria will be applied. Continuation: baseline BMI explicitly not re-evaluated; continuation based on 25% AHI improvement, lifestyle adherence, BMI >=27, and no reasons for non-coverage. Exclusions are based on SURMOUNT-OSA trial exclusion criteria.

Policy effective June 2, 2026 · verified June 5, 2026 · source: hmo-exchange-prior-authorization-criteria-en.pdf

Why Zepbound requests get denied by Kaiser Permanente Mid-Atlantic

Based on what this policy asks for. Fix these before the first submission.

Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
Qualifying weight-related condition not documented with its own diagnosis code.
No documented diet and exercise program.
Required prior medication trials not documented.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Kaiser Permanente Mid-Atlantic cover Zepbound?: Kaiser Permanente Mid-Atlantic covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance, ACA Marketplace, and Federal Employee Program.
What BMI do you need for Zepbound under Kaiser Permanente Mid-Atlantic?: For weight loss on Employer / Commercial Insurance plans, Kaiser Permanente Mid-Atlantic requires a BMI of 27 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with Kaiser Permanente Mid-Atlantic?: Initial approvals last 6 months, and renewals are granted in 6-month periods.
What does Kaiser Permanente Mid-Atlantic require to renew Zepbound?: At least 5% weight loss from the starting weight and Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI >=27: 6-month reauthorization. Prior semaglutide step therapy and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members.
How current is this information?: This page reflects Kaiser Permanente Mid-Atlantic's written policy as of June 2, 2026, last verified against the source document on June 5, 2026.

Does Kaiser Permanente Mid-Atlantic cover Zepbound?

Quick answer · Weight Loss

Zepbound for Weight Loss

Employer / Commercial Insurance

What you need to qualify

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when

ACA Marketplace

What you need to qualify

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when

Federal Employee Program

What you need to qualify

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when

Zepbound for Osa

Employer / Commercial Insurance

What you need to qualify

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when

ACA Marketplace

What you need to qualify

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when

Federal Employee Program

What you need to qualify

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when

Why Zepbound requests get denied by Kaiser Permanente Mid-Atlantic

Frequently asked questions

Other medications under Kaiser Permanente Mid-Atlantic

Zepbound coverage under other plans